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Accepted 7 October 2013It has beenwell documented that leukoreduction of blood
products results in fewer febrile nonhemolytic transfusion
reactions, less HLA alloimmunization and platelet refracto-
riness, and less transmission of cytomegalovirus (CMV) to
high-risk CMV-naïve patients [1-4]. This has led to wide-
spread adoption of leukoreduction practices in most blood
banks over the past 20 years. The debate that remains
regarding transfusion-transmitted CMV (TT-CMV) is whether
leukoreduced blood products are safe enough to discontinue
the practice of screening blood donors for CMV seropositivity
for patients at very high risk of developing CMV disease, such
as seronegative recipients (R-) of allogeneic hematopoietic
cell transplants (HCT) from seronegative donors (D-).
The only randomized clinical trial directly comparing the
use of leukocyte reduced blood products using bedside
ﬁltration versus CMV seronegative products for HCT re-
cipients was published in 1995 and reported no difference in
the incidence of CMV infection occurring after day 21 after
transplantation [5]. However, when all infections were
evaluated, including those occurring before day 21, the
incidence of CMV disease was higher in the group receiving
ﬁltered blood. Of course, much has changed since this trial,
including improvements in both ﬁltration methods and CMV
detection. A large prospective cohort study performed later
at the same center found that each ﬁltered RBC unit from a
CMV seropositive blood donor was associated with a 32%
increase in the odds of TT-CMV infection [6]. By this time,
preemptive therapy with ganciclovir for CMV infection had
already been established and so therewas only 1 case of CMV
disease among the 807 patients. Given concerns over a re-
sidual increased risk of TT-CMV in leukoreduced CMV posi-
tive blood products, many transplantation centers practicing
universal leukoreduction continue to use preferentially
CMV-negative products for these and other high-risk patient
populations [7,8].
In this issue of Biology of Blood and Marrow Trans-
plantation, Kekre at al. examined the question of whether, in
the era of universal leukoreduction, a difference in TT-CMV
incidence could be detected between D-/R- allogeneic HCT
recipients who received leukoreduced blood products from
CMV seronegative donors only versus leukoreduced blood
products without knowledge of the CMV status [9]. In thisFinancial disclosure: See Acknowledgments on page 1660.
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http://dx.doi.org/10.1016/j.bbmt.2013.10.007cohort, which spanned over a decade (1999 to 2012),
166 patients were evaluated. Importantly, patients were
screened weekly with CMV PCR from engraftment until
discontinuation of immune suppression. Patients in the
2 groups required similar numbers of red blood cell and
single donor platelets, but patients in the leukoreduction
only arm received signiﬁcantly fewer random donor platelet
transfusions. CMV infection was detected in 4 of 166 pa-
tients; 3 patients who received only CMV seronegative blood
products and 1 patient who received leukoreduced only
blood products. There were no conﬁrmed cases of CMV dis-
ease, although 2 patients were suspected to have CMV
pneumonia.
Interestingly, CMV serology data for all of the transfused
blood products was available from the Canadian Blood Ser-
vices for 82% of the patients in the leukoreduced only arm.
Only approximately one quarter of the transfused RBC units
and one half of the platelet units were CMV positive, indi-
cating that the CMV seroprevalence of Canadian blood
donors is likely much lower than that of the general popu-
lation. This has important implications for the applicability
of these data to centers where the CMV seroprevalence of
blood donors is much higher. An average incidence of TT-
CMV of 1.3% with an upper 95% conﬁdence interval of 9.5%
for high-risk patients receiving “only” leukoreduced blood
products is less reassuring when the majority of those blood
products were actually CMV negative. It is unknown what
the incidence might be if 70% or 80% of the blood products
were from seropositive donors. With a relatively small
sample size, a comparison between 2 groups, both of whom
received leukoreduced blood products, could not have
adequate power to detect a moderate difference in TT-CMV
between patients who received all CMV negative blood
products and those who received mostly CMV negative
blood products. In fact, a study designed to prove that the
use of unscreened leukoreduced blood products was non-
inferior to using only CMV seronegative leukoreduced blood
products for the prevention of TT-CMV after HCT would
require several thousand patients. Clearly, this is beyond
anything even the largest HCT centers can accomplish alone
and might only be possible utilizing existing HCT trial net-
works or registries.
What remains consistent and very reassuring, however, is
the absence of signiﬁcant morbidity or mortality from TT-
CMV in HCT patients who undergo routine surveillance and
are treated pre-emptively when infection is detecteddas all
of the patients were in this current study. However current
guidelines do not include D-/R- allogeneic HCT recipients in
patients considered at risk for post-transplantation CMV
disease [10]. In an international survey of HCT centers
reﬂecting infection prevention practices through 2003, 36%
of centers were not routinely performing CMV surveillance
on this patient group [7]. Any cost savings realized from
discontinuation of testing blood donors for CMV may be
balanced by the additional costs associated with monitoring
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centers where this is not routinely done and the costs of
treatment of CMV disease, which will predictably occur in
approximately 1 in 200 patients with primary CMV infection.
Although it may verywell be safe to discontinue testing of
blood product CMV serostatus for HCT patients if post-
transplantation surveillance and pre-emptive therapy is
performed, the study by Kekre et al. does not conclusively
show this due to the small sample size. Additionally, blood
centers would still likely be asked to maintain a CMV-
negative blood supply for other high-risk groups where
surveillance is not standard care, such as in fetal transfusion
and transfusion to low-birth-weight infants. An observa-
tional clinical trial, which aims to determine the incidence of
TT-CMV in 1300 low-birth-weight infants who receive CMV
seronegative, leukoreduced blood products, is ongoing
(NCT00907686). The investigators will also examine the in-
dividual blood products with nucleic acid testing (NAT);
these data may provide important insight into CMV trans-
mission from window-period blood donors and also about
the feasibility of performing CMV NAT in donated blood
products [11]. CMV NAT of blood products may eventually
help us to identify CMV transmitters, both seropositive and
seronegative, and to offer all of our high-risk patients a CMV-
safer blood product.
Because some portion of CMV infection in HCT patients
will inevitably progress to CMV disease with its associated
morbidity, mortality, and treatment expense, until we have
data from adequately powered studies demonstrating
that in the era of universal leukoreduction using CMV-
seropositive blood products does not increase the risk of
TT-CMV over that of CMV-seronegative products, it would
be premature to abandon CMV screening of our blood
supply for these patients unless patients are undergoing
post-transplantation CMV surveillance and preemptive
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